Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Evofem Biosciences's revenue for the twelve months ending Jun 30, 2026 was $18.05M, up 4.5% year over year. For fiscal 2025 it was $20.18M, up 4.2% from the year before. The highest annual figure on record is $20.18M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.18M | +4.2% |
| FY2024 | Dec 31, 2024 | $19.36M | +6.3% |
| FY2023 | Dec 31, 2023 | $18.22M | +8.2% |
| FY2022 | Dec 31, 2022 | $16.84M | +104.2% |
| FY2021 | Dec 31, 2021 | $8.24M | +1748.4% |
| FY2020 | Dec 31, 2020 | $446.00K | – |
| FY2019 | Dec 31, 2019 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.63M | -45.4% |
| Q1 FY2026 | Mar 31, 2026 | $899.00K | +6.4% |
| Q4 FY2025 | Dec 31, 2025 | $9.56M | +34.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.95M | +10.1% |
| Q2 FY2025 | Jun 30, 2025 | $4.83M | +16.0% |
| Q1 FY2025 | Mar 31, 2025 | $845.00K | -76.5% |
| Q4 FY2024 | Dec 31, 2024 | $7.10M | +189.0% |
| Q3 FY2024 | Sep 30, 2024 | $4.50M | -22.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.16M | +2198.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.60M | -43.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.46M | -59.3% |
| Q1 FY2023 | Mar 31, 2023 | $5.81M | +36.7% |
| Q4 FY2022 | Dec 31, 2022 | $181.00K | -94.9% |
| Q3 FY2022 | Sep 30, 2022 | $6.37M | +272.1% |
| Q2 FY2022 | Jun 30, 2022 | $6.03M | +224.9% |
| Q1 FY2022 | Mar 31, 2022 | $4.25M | +284.7% |
| Q4 FY2021 | Dec 31, 2021 | $3.57M | +2025.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.71M | +515.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.86M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.11M | – |
| Q4 FY2020 | Dec 31, 2020 | $168.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $278.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
See a number that looks wrong?